

CORRECTED VERSION

(19) World Intellectual Property Organization
International Bureau(43) International Publication Date
10 January 2008 (10.01.2008)

PCT

(10) International Publication Number
WO 2008/005511 A8

(51) International Patent Classification:

C07D 231/56 (2006.01) A61K 31/416 (2006.01)
 C07D 403/14 (2006.01) A61K 31/437 (2006.01)
 C07D 471/04 (2006.01) A61P 31/14 (2006.01)
 A61K 31/4035 (2006.01)

W. [US/US]; 2020 Kentmore, Longmont, Colorado 80501 (US).

(21) International Application Number:

PCT/US2007/015530

(22) International Filing Date: 5 July 2007 (05.07.2007)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:

60/818,914 5 July 2006 (05.07.2006) US
 60/819,128 6 July 2006 (06.07.2006) US

(71) Applicants (for all designated States except US): **INTERMUNE, INC.** [US/US]; 3280 Bayshore Boulevard, Brisbane, California 94005 (US). **ARRAY BIOPHARMA, INC.** [US/US]; 3200 Walnut Street, Boulder, Colorado 80301 (US).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **BLATT, Lawrence M.** [US/US]; 10 Shoreview Ave., San Francisco, California 94121 (US). **SEIWERT, Scott** [US/US]; 828 Rockaway Beach Ave., Pacifica, California 94044 (US). **BEIGELMAN, Leonid** [US/US]; 991 E. Grant Place, San Mateo, California 94402 (US). **KERCHEK, Timothy** [US/US]; 5522 Mesa Top Court, Boulder, Colorado 80301 (US). **KENNEDY, April L.** [US/US]; 1225 Emerson St., #A, Denver, Colorado 80218 (US). **ANDREWS, Steven**

(74) Agent: **MALLON, Joseph J.**; KNOBBE MARTENS OLSON & BEAR, LLP, 2040 Main Street, Fourteenth Floor, Irvine, California 92614 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).




Published:

— with international search report

(88) Date of publication of the international search report:
31 July 2008

[Continued on next page]

(54) Title: NOVEL INHIBITORS OF HEPATITIS C VIRUS REPLICATION



(57) Abstract: The embodiments provide compounds of the general Formula (I), as well as compositions, including pharmaceutical compositions, comprising a, subject compound. The embodiments provide compounds of the general Formula (II), as well as compositions, including pharmaceutical compositions, comprising a subject compound, The embodiments provide compounds of the general Formula (III), as well as compositions, including pharmaceutical compositions, comprising a subject compound. The embodiments further provide treatment methods, including methods of treating a hepatitis C virus infection and methods of treating liver fibrosis, the methods generally involving administering to an individual in need thereof an effective amount of a subject compound or composition.

WO 2008/005511 A8



(48) Date of publication of this corrected version:

19 March 2009

(15) Information about Correction:

see Notice of 19 March 2009